GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+1.57%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$320M
AUM Growth
+$320M
(-10%)
Cap. Flow
-$21M
Cap. Flow
% of AUM
-6.58%
Top 10 Holdings %
Top 10 Hldgs %
46.9%
Holding
64
New
14
Increased
9
Reduced
10
Closed
11
Top Buys
| 1 |
RAPT Therapeutics
RAPT
|
$18.1M |
| 2 |
Allogene Therapeutics
ALLO
|
$7.17M |
| 3 |
Galapagos
GLPG
|
$5.17M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
$4.93M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$4.59M |
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$9.66M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
$8.86M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$6.79M |
| 4 |
VistaGen Therapeutics
VTGN
|
$6.75M |
| 5 |
iShares Russell 2000 ETF
IWM
|
$6.63M |
Sector Composition
| 1 | Healthcare | 96.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
|
SAGE
52
DELISTED
Sage Therapeutics
SAGE
| – | – |
-30,000
| Closed | -$2.25M |
|
53
Invesco QQQ Trust
QQQ
$364B
| – | – |
0
| – | – |
|
54
Novavax
NVAX
$1.2B
| – | – |
-17,500
| Closed | -$3.17M |
|
55
Nuvation Bio
NUVB
$1.08B
| – | – |
-500,000
| Closed | -$4.96M |
|
56
Korro Bio
KRRO
$245M
| – | – |
0
| – | – |
|
|
57
iShares Russell 2000 ETF
IWM
$66.6B
| – | – |
-30,000
| Closed | -$6.63M |
|
58
Immunovant
IMVT
$2.91B
| – | – |
-250,000
| Closed | -$4.01M |
|
59
Precision BioSciences
DTIL
$59.5M
| – | – |
-200,000
| Closed | -$2.07M |
|
60
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-500,000
| Closed | -$5.09M |
|
61
ARK Genomic Revolution ETF
ARKG
$1.05B
| – | – |
0
| – | – |
|
62
Aptevo Therapeutics
APVO
$5.56M
| – | – |
-50,000
| Closed | -$1.53M |
|
|
63
Apellis Pharmaceuticals
APLS
$3.51B
| – | – |
-225,000
| Closed | -$9.66M |
|
64
FibroGen
FGEN
$48.4M
| – | – |
-125,000
| Closed | -$4.34M |
|